Glanbia plc (GLAPY)
| Market Cap | 5.50B +90.0% |
| Revenue (ttm) | 3.95B +2.8% |
| Net Income | 183.30M +11.3% |
| EPS | 0.72 +16.0% |
| Shares Out | n/a |
| PE Ratio | 30.01 |
| Forward PE | 15.19 |
| Dividend | 2.46 (2.41%) |
| Ex-Dividend Date | Mar 20, 2026 |
| Volume | 153 |
| Average Volume | 335 |
| Open | 102.21 |
| Previous Close | 98.24 |
| Day's Range | 102.21 - 102.21 |
| 52-Week Range | 71.00 - 102.21 |
| Beta | 0.53 |
| RSI | 66.78 |
| Earnings Date | Aug 6, 2026 |
About Glanbia
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services a... [Read more]
Financial Performance
In fiscal year 2025, Glanbia's revenue was $3.95 billion, an increase of 2.78% compared to the previous year's $3.84 billion. Earnings were $183.30 million, an increase of 11.29%.
Financial StatementsNews
Glanbia price target raised to EUR 21.50 from EUR 18.50 at Deutsche Bank
Deutsche Bank analyst Damian McNeela raised the firm’s price target on Glanbia (GLAPF) to EUR 21.50 from EUR 18.50 and keeps a Buy rating on the shares. Published first on…
Glanbia price target raised to EUR 18.30 from EUR 18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 18.30 from EUR 18 and keeps an Equal Weight rating on the shares.
The week ahead in business: ECB decision on interest rates, and CRH, Glanbia and AIB among host of firms to release Q1 figures
The governing council of the European Central Bank (ECB) will meet for two days this week, and will announce its decision on monetary policy at lunchtime on Thursday. However, ECB president Christine ...
Glanbia price target lowered to EUR 18 from EUR 18.20 at Morgan Stanley
Morgan Stanley analyst David Roux lowered the firm’s price target on Glanbia (GLAPF) to EUR 18 from EUR 18.20 and keeps an Equal Weight rating on the shares. Published first…
Glanbia price target raised to EUR 21 from EUR 19 at Mizuho
Mizuho analyst John Baumgartner raised the firm’s price target on Glanbia (GLAPF) to EUR 21 from EUR 19 and keeps an Outperform rating on the shares. The firm views the…
Glanbia downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Glanbia (GLAPF) to Hold from Buy.
Glanbia downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Glanbia (GLAPF) to Equal Weight from Overweight with a price target of EUR 18.20, down from EUR 18.30. The firm says increasing whey input costs could drive…
Glanbia price target raised to EUR 18.80 from EUR 18.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 18.80 from EUR 18.50 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 18.50 from EUR 18.80 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Glanbia (GLAPF) to EUR 18.50 from EUR 18.80 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 18.80 from EUR 19 at Morgan Stanley
Morgan Stanley analyst David Roux lowered the firm’s price target on Glanbia (GLAPF) to EUR 18.80 from EUR 19 and keeps an Overweight rating on the shares. Published first on…
Glanbia price target raised to EUR 17.90 from EUR 17.05 at Berenberg
Berenberg raised the firm’s price target on Glanbia (GLAPF) to EUR 17.90 from EUR 17.05 and keeps a Buy rating on the shares.
Glanbia to sell Slimfast US to Heartland Food Products group of US
Irish-based nutrition supplement maker Glanbia on Wednesday said it had agreed to sell its weight management brand SlimFast US to Heartland Food Products Group for an undisclosed sum.
Flax Protein Markets and Companies Analysis Report 2025 with Forecasts to 2029 & 2034 - Featuring Glanbia Nutritionals, Grain Millers, Myprotein, Linwoods Health Foods, Bioriginal Food & Science Corp. and More
Explore the booming Flax Protein Market: projected to soar from $38.54B in 2024 to $56.42B by 2029, driven by the rise in plant-based diets and demand for minimally processed foods. Explore the boomin...
Glanbia shares jump after 'better than feared' first quarter
Shares in nutrition supplement maker Glanbia jumped 10% on Wednesday after analysts pointed to a "better than feared" first quarter performance that allowed the Irish group to maintain its full year e...
Glanbia price target lowered to EUR 19 from EUR 24 at Mizuho
Mizuho lowered the firm’s price target on Glanbia (GLAPF) to EUR 19 from EUR 24 and keeps an Outperform rating on the shares. The firm lowered estimates, saying March consumer…
Glanbia price target lowered to EUR 13.50 from EUR 18.90 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Glanbia (GLAPF) to EUR 13.50 from EUR 18.90 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 16.50 from EUR 17.50 at Barclays
Barclays lowered the firm’s price target on Glanbia (GLAPF) to EUR 16.50 from EUR 17.50 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 18 from EUR 24 at Berenberg
Berenberg lowered the firm’s price target on Glanbia (GLAPF) to EUR 18 from EUR 24 and keeps a Buy rating on the shares.
Glanbia price target lowered to EUR 15 from EUR 20 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Glanbia (GLAPF) to EUR 15 from EUR 20 and keeps a Buy rating on the shares.
Supplements producer Glanbia's shares dive on profit warning
Shares in nutrition supplement maker Glanbia slid by 15% on Wednesday after it warned that it expects earnings to fall by up to 11% this year, hit by a longer than expected rise in the cost of whey, a...
Glanbia price target lowered to EUR 18.90 from EUR 21.10 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Glanbia (GLAPF) to EUR 18.90 from EUR 21.10 and keeps an Overweight rating on the shares.
Glanbia price target lowered to EUR 20 from EUR 21 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Glanbia (GLAPF) to EUR 20 from EUR 21 and keeps a Buy rating on the shares.
Glanbia price target lowered to EUR 19.50 from EUR 21 at Barclays
Barclays lowered the firm’s price target on Glanbia (GLAPF) to EUR 19.50 from EUR 21 and keeps an Overweight rating on the shares.
Glanbia price target raised to EUR 21.10 from EUR 19.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Glanbia (GLAPF) to EUR 21.10 from EUR 19.50 and keeps an Overweight rating on the shares.
Glanbia upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux upgraded Glanbia to Buy from Hold with an EUR 18.50 price target.